M. Untch
Research Subjects
M. Untch has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
B Mayer
1 shared publicationC M Kurbacher
1 shared publicationC. Crohns
1 shared publicationC. Kurbacher
1 shared publicationE. Langer
1 shared publicationG. Konecny
1 shared publication
Latest Publications
- 1 January 2003
- Published by Springer Nature
- Vol. 161, 146-158
Chemosensitivity Testing in Gynecologic Oncology — Dream or Reality?
Cell culture and animal models have played an essential role in the research of new principles of therapy. Many methods for the individualized testing of therapy sensitivity and resistance have been developed, for example, the clonogenic assay. Presently, the ATP-TCA is commercially available as a testing kit. This review gives an overview of the tumor samples that were tested in the oncologic laboratory in the Department of Obstetrics and Gynecology, Munich Grosshadern between 1993 and 2001. All target parameters show a clear trend in favor of sequential, dose-intensified Epirubicin/Paclitaxel therapy. If this trend remains valid for the total number of patients, a significant impact of this new principle of therapy can be expected. By individualized planning of therapy with ATP-TCA testing, therapy in the individual patient could already be performed by the examination of sensitivity in the preoperative biopsy specimen.
- 1 January 2003
- Published by Springer Nature
- Vol. 161, 146-158
Chemosensitivity Testing in Gynecologic Oncology — Dream or Reality?
Cell culture and animal models have played an essential role in the research of new principles of therapy. Many methods for the individualized testing of therapy sensitivity and resistance have been developed, for example, the clonogenic assay. Presently, the ATP-TCA is commercially available as a testing kit. This review gives an overview of the tumor samples that were tested in the oncologic laboratory in the Department of Obstetrics and Gynecology, Munich Grosshadern between 1993 and 2001. All target parameters show a clear trend in favor of sequential, dose-intensified Epirubicin/Paclitaxel therapy. If this trend remains valid for the total number of patients, a significant impact of this new principle of therapy can be expected. By individualized planning of therapy with ATP-TCA testing, therapy in the individual patient could already be performed by the examination of sensitivity in the preoperative biopsy specimen.
- 10 October 2002
- Vol. 144 (41) , 37-9
[Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
Development of metastases in cancer patients is usually due to tumour cells seeding from the primary. These disseminated cells can be detected in blood or bone marrow with the aid of immunocytochemical methods. The clinical significance of this is, however, still controversial. With the aim of determining the prognostic value of disseminated tumour cells, a meta-analysis of 20 publications reporting results based on data collected from a total of 2494 breast cancer patients, was carried out. The outcome of the meta-analysis was that 14 of the 20 studies provided evidence suggesting positive bone marrow findings to be an unfavorable prognostic factor. Five out of twelve studies provided multivariate analytic evidence of an impact of bone marrow status on recurrence-free survival. In five out of twelve studies, a univariate analysis showed a positive bone marrow finding to correlate significantly with overall survival, while a multivariate analysis found such a correlation in only two out of six studies. Owing to a lack of standardization, the results of the individual studies are not directly comparable. Against this background it is too early to say whether the detection of disseminated tumour cells in the bone marrow can be used as a prognostic factor with an impact on therapeutic strategies.
- 10 October 2002
- Vol. 144 (41) , 37-9
[Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
Development of metastases in cancer patients is usually due to tumour cells seeding from the primary. These disseminated cells can be detected in blood or bone marrow with the aid of immunocytochemical methods. The clinical significance of this is, however, still controversial. With the aim of determining the prognostic value of disseminated tumour cells, a meta-analysis of 20 publications reporting results based on data collected from a total of 2494 breast cancer patients, was carried out. The outcome of the meta-analysis was that 14 of the 20 studies provided evidence suggesting positive bone marrow findings to be an unfavorable prognostic factor. Five out of twelve studies provided multivariate analytic evidence of an impact of bone marrow status on recurrence-free survival. In five out of twelve studies, a univariate analysis showed a positive bone marrow finding to correlate significantly with overall survival, while a multivariate analysis found such a correlation in only two out of six studies. Owing to a lack of standardization, the results of the individual studies are not directly comparable. Against this background it is too early to say whether the detection of disseminated tumour cells in the bone marrow can be used as a prognostic factor with an impact on therapeutic strategies.